ORGANIGRAM GLOBAL INC.
OGI evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for OGI—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · OGI
Organigram Global Inc. is a Canadian cannabis company that files periodic reports with the U.S. SEC as a foreign private issuer, with its principal executive offices in Toronto, Ontario.
Key risk: Regulatory and compliance burden
Market Cap
$171.3M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Sep 30, 2024.
Organigram Global Inc. is a Canadian cannabis company that files periodic reports with the U.S. SEC as a foreign private issuer, with its principal executive offices in Toronto, Ontario.
- Organigram Global Inc. is a foreign private issuer filing Form 6-K with the SEC, with principal executive offices at 145 King Street West, Suite 1400, Toronto, Ontario, Canada [sec · filed 2026-08-04].
- The company reported cash & equivalents of $106.7M and shareholders' equity of $508.1M as of 2024-09-30 [sec].
- Organigram has filed multiple news releases and material change reports in 2026, including on August 4, May 6, April 15, March 30, March 23, March 10, March 5, March 3, February 24, and February 18 [sec].
- The company filed a Management's Discussion and Analysis for the three months ended December 31, 2025, on February 10, 2026 [sec · filed 2026-02-10].
What works
- Organigram maintains a substantial cash position of $106.7M as of 2024-09-30, providing liquidity for operations and strategic initiatives [sec].
- The company has a strong equity base of $508.1M as of 2024-09-30, indicating a solid financial foundation [sec].
- Organigram is actively communicating with the market through frequent news releases and regulatory filings, suggesting ongoing corporate activity and transparency [sec].
What to weigh
- The company has filed multiple material change reports in 2026, which may indicate significant operational or strategic shifts that could introduce uncertainty [sec · filed 2026-03-03].
- As a foreign private issuer, Organigram is subject to both Canadian and U.S. regulatory requirements, which may increase compliance costs and complexity [sec].
- The cannabis industry faces regulatory and market risks in both Canada and the U.S., which could impact Organigram's financial performance [sec].
From the filings
Quoted directly from source documents.
Organigram Global Inc. is a foreign private issuer filing Form 6-K with the SEC.
“FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934”
SEC filings · August 4, 2026
The company's principal executive offices are in Toronto, Ontario.
“145 King Street West, Suite 1400 Toronto, Ontario ,Canada M5H 1J8”
SEC filings · August 4, 2026
Organigram filed a Management's Discussion and Analysis for the three months ended December 31, 2025.
“Management's Discussion and Analysis for the three months ended December 31, 2025”
SEC filings · February 10, 2026
The company filed a material change report in March 2026.
“Material Change Report dated March 2, 2026”
SEC filings · March 3, 2026
Risks & what to watch (3)›
Key risks
- Regulatory and compliance burden — As a foreign private issuer, Organigram must comply with both Canadian and U.S. securities laws, increasing complexity and costs [sec].
- Cannabis industry volatility — The cannabis sector is subject to evolving regulations, market fluctuations, and competitive pressures that could affect Organigram's performance [sec].
- Dependence on frequent disclosures — Multiple material change reports in 2026 suggest significant corporate events that may introduce operational or financial uncertainty [sec · filed 2026-03-03].
What to watch
- Future financial results and updates from the Management's Discussion and Analysis for the three months ended December 31, 2025 [sec · filed 2026-02-10].
- Any material changes or strategic announcements following the multiple news releases and material change reports filed in 2026 [sec].
- Regulatory developments in the Canadian and U.S. cannabis markets that could impact Organigram's business [sec].
Sources: SEC filings · Generated August 21, 2026 · How we verify sources →
Run ORGANIGRAM GLOBAL INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available ORGANIGRAM GLOBAL INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
73
Total value held
$7.7M
| Holder | Shares | Value |
|---|---|---|
| renaissance technologies llc | 1,640,048 | $2.2M |
| advisorshares investments llc | 947,440 | $1.3M |
| goldman sachs group inc | 571,369 | $766K |
| morgan stanley | 364,184 | $488K |
| lazard asset management llc | 346,796 | $465K |
| bank of montreal /can/ | 238,054 | $317K |
| susquehanna international group, llp | 202,753 | $272K |
| formidable asset management, llc | 156,749 | $263K |
| leonteq securities ag | 138,511 | $256K |
| dimensional fund advisors lp | 173,884 | $233K |
Showing top 10 of 73 institutional holders of ORGANIGRAM GLOBAL INC.. Open the full 13F history after sign-in.
Governance
Frequently asked questions
What is the AI investment thesis for ORGANIGRAM GLOBAL INC.?
Organigram Global Inc. is a Canadian cannabis company that files periodic reports with the U.S. SEC as a foreign private issuer, with its principal executive offices in Toronto, Ontario.
Who is the CEO of ORGANIGRAM GLOBAL INC.?
Mr. James H. Yamanaka is the chief executive officer of ORGANIGRAM GLOBAL INC. (OGI).
Where is ORGANIGRAM GLOBAL INC. headquartered?
ORGANIGRAM GLOBAL INC. (OGI) is headquartered in Toronto, ON, Canada.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.